Duloxetine
Product Images NDC 45865-816

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 45865-816). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp30mg (813 60)

Duloxetine DR Capsules 30mg label, generic for Cymbalta. The label shows a package size of 60 capsules and includes bilingual warning text about possible side effects such as nausea, dizziness, and dry mouth. It specifies the appearance of capsules as blue and white and lists the manufacturer as Dr. Reddy's Laboratories, Bachepalli India. The label includes spaces for lot number and expiration date.*

FDA Label Image

Pdp60mg (816 30)

Label for Duloxetine DR Capsules 60 mg, generic for Cymbalta, with a package count of 30 capsules. The label includes lot and expiration information fields, active ingredient strength, and warnings about possible side effects like nausea, dizziness, and dry mouth. Manufactured by Dr. Reddy's Laboratories/Bachepalli India, the label is bilingual in English and Spanish and displays the NDC number 45865-0816-30.*

FDA Label Image

Figure1 (Figure1)

A line graph illustrating the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine Hydrochloride at doses of 60 mg twice daily (BID), 60 mg once daily (QD), and 20 mg QD, along with a placebo group, showing varying response levels across these treatments.*

FDA Label Image

Figure2 (Figure2)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine Hydrochloride 60mg BID, Duloxetine Hydrochloride 60mg QD, and Placebo, showing higher patient improvement percentages for Duloxetine groups relative to placebo across increasing pain improvement percentages.*

FDA Label Image

Figure5 (Figure5)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline, comparing Duloxetine 60 mg/120 mg once daily and placebo. The graph uses two curves labeled for the treatment groups to illustrate differences in patient improvement over the range of pain reduction percentages.*

FDA Label Image

Figure6 (Figure6)

A line graph comparing percentage of patients improved in pain over percent improvement from baseline for Duloxetine 60 mg once daily versus placebo. The vertical axis shows percentage of patients improved, while the horizontal axis shows percent improvement in pain from baseline (BOCF). Duloxetine consistently shows higher patient improvement than placebo.*

FDA Label Image

Figure7 (Figure7)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF), comparing Duloxetine 60 mg/120 mg once daily to placebo. The graph plots patient improvement across varying pain reduction percentages, with Duloxetine demonstrating higher improvement rates over placebo.*

FDA Label Image

Structure (Structure)

Chemical structure of duloxetine hydrochloride. The diagram shows the molecular framework including thiophene, naphthyl, and amino groups along with the hydrochloride association.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.